TXMD
TherapeuticsMD, Inc.
$2.11
-0.05 (-2.31%)
At close · Jul 2
View the 10-Q filed May 12, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$24.42M
Shares
11,574,362
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.11
Open$2.16
Day$2.01–2.19
52W$0.99–2.95
Avg vol 30d53K
Short int46K · 0.4% float · 1.0d
Short vol19%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+13% above
+
Price vs 50-day avg
+2% above
◦
RSI (14)
52 · neutral
+
MACD trend
positive
◦
52-week position
57% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $2 — 50d above 200d
+
Institutional flow
+11% holders QoQ · +10 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
0.40% of float · ▼ -10.2% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
50 holders — near 3-yr high, broad support
Fundamentals
Fair
+
Revenue growth
+35% Y/Y
+
Gross margin
74%, contracting
+
EPS growth
+74% Y/Y
−
Free cash flow
$-142.7M
−
Valuation
P/E 105.5 · rich
−
Balance sheet
net debt $183.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+13% above
Bullish
Price vs 50-day avg
+2% above
Bullish
RSI (14)
52 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
57% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.40% of float · ▼ -10.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 57%
52-wk high $3
vs 200-day avg +13%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXMD
this stock
TherapeuticsMD, Inc.
|
$24.42M | +29.4% | +35.3% | 105.5 | 0.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.99B | +7.6% | — | — | 0.3% |
|
GALDY
Galderma Group AG/ADR
|
$52.48B | +8.0% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.25B | -2.9% | — | — | 0.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXMD | +3.9% | +7.1% | +2.4% | -4.5% | +29.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +2.5% | +8.4% | -5.6% | -4.3% | +20.2% |